[
  {
    "ts": "2026-01-16T01:00:00+00:00",
    "headline": "Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs",
    "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plan",
    "url": "https://finance.yahoo.com/news/antengene-presents-jpm-strong-clinical-010000312.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "769b4637-23f1-3f69-a1b8-bd19936f7b28",
      "content": {
        "id": "769b4637-23f1-3f69-a1b8-bd19936f7b28",
        "contentType": "STORY",
        "title": "Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs",
        "description": "",
        "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plan",
        "pubDate": "2026-01-16T01:00:00Z",
        "displayTime": "2026-01-16T01:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583",
          "originalWidth": 400,
          "originalHeight": 170,
          "caption": "Logo (PRNewsfoto/Antengene Corporation Limited)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iX4d3zH6.489mYmi5zPGYg--~B/aD0xNzA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 400,
              "height": 170,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p3TrWaua._04_VbJue7uzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/antengene-presents-jpm-strong-clinical-010000312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/antengene-presents-jpm-strong-clinical-010000312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "6996.HK"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T00:55:49+00:00",
    "headline": "Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference",
    "summary": "Bioventus (NASDAQ:BVS) executives outlined a multi-year turnaround story and a set of new growth priorities during a presentation and Q&A session hosted by J.P. Morgan healthcare analyst David Brumund. CEO Rob Claypoole and CFO Mark Singleton emphasized recent margin and cash flow improvements,",
    "url": "https://www.marketbeat.com/instant-alerts/bioventus-details-turnaround-plan-four-growth-drivers-at-jp-morgan-conference-2026-01-15/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "29d3fc04-329b-36b3-a8ce-7c153524e359",
      "content": {
        "id": "29d3fc04-329b-36b3-a8ce-7c153524e359",
        "contentType": "STORY",
        "title": "Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference",
        "description": "",
        "summary": "Bioventus (NASDAQ:BVS) executives outlined a multi-year turnaround story and a set of new growth priorities during a presentation and Q&A session hosted by J.P. Morgan healthcare analyst David Brumund. CEO Rob Claypoole and CFO Mark Singleton emphasized recent margin and cash flow improvements,",
        "pubDate": "2026-01-16T00:55:49Z",
        "displayTime": "2026-01-16T00:55:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/2c5ba8e5cc51cf9a63ff65b609a5c083",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Bioventus logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N259AWQ6U4wqRJyP0RqcBQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/2c5ba8e5cc51cf9a63ff65b609a5c083.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lzg2IRcuf7d3JtHrmAgmSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/2c5ba8e5cc51cf9a63ff65b609a5c083.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/bioventus-details-turnaround-plan-four-growth-drivers-at-jp-morgan-conference-2026-01-15/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bioventus-details-turnaround-plan-four-005549389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BVS"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T03:15:53+00:00",
    "headline": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
    "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
    "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bcd9de05-aef9-38cf-b319-2387897ab0ad",
      "content": {
        "id": "bcd9de05-aef9-38cf-b319-2387897ab0ad",
        "contentType": "STORY",
        "title": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
        "description": "",
        "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
        "pubDate": "2026-01-16T03:15:53Z",
        "displayTime": "2026-01-16T03:15:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORIC"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T08:07:08+00:00",
    "headline": "Best savings account deals that offer above-inflation rates",
    "summary": "Check the best savings accounts to find a top-rated deal that works for you.",
    "url": "https://uk.finance.yahoo.com/news/best-savings-accounts-deals-inflation-rates-130148742.html",
    "source": "Yahoo Finance UK",
    "provider": "yfinance",
    "raw": {
      "id": "ef17bbd9-c32a-4aa7-a694-2847b774e131",
      "content": {
        "id": "ef17bbd9-c32a-4aa7-a694-2847b774e131",
        "contentType": "STORY",
        "title": "Best savings account deals that offer above-inflation rates",
        "description": "",
        "summary": "Check the best savings accounts to find a top-rated deal that works for you.",
        "pubDate": "2026-01-16T08:07:08Z",
        "displayTime": "2026-01-16T08:07:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-01/c4098550-ed45-11f0-a7e7-fc3b56a64e15",
          "originalWidth": 6016,
          "originalHeight": 4003,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AD0j7nWtdf0wJk_ByGH7GQ--~B/aD00MDAzO3c9NjAxNjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-01/c4098550-ed45-11f0-a7e7-fc3b56a64e15.cf.webp",
              "width": 6016,
              "height": 4003,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8P_RmelKwFT.WRlvG.oB5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-01/c4098550-ed45-11f0-a7e7-fc3b56a64e15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance UK",
          "url": "http://uk.finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/best-savings-accounts-deals-inflation-rates-130148742.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/best-savings-accounts-deals-inflation-rates-130148742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAN.MC"
            },
            {
              "symbol": "^FTSE"
            },
            {
              "symbol": "GBPEUR=X"
            },
            {
              "symbol": "GBP=X"
            },
            {
              "symbol": "EUR=X"
            },
            {
              "symbol": "NWG"
            },
            {
              "symbol": "TSCDF"
            },
            {
              "symbol": "TSCDY"
            },
            {
              "symbol": "GBPUSD=X"
            },
            {
              "symbol": "USD=X"
            },
            {
              "symbol": "GBP=X"
            },
            {
              "symbol": "BCS"
            },
            {
              "symbol": "NBS.L"
            },
            {
              "symbol": "SAN"
            },
            {
              "symbol": "GS"
            },
            {
              "symbol": "TSCO.L"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]